



# PneumoRecs VaxAdvisor

New mobile app to navigate the challenge of implementing the U.S. pneumococcal vaccination schedule

**Alison P. Albert, MPH, CHES**

National Center for Immunization and Respiratory Diseases,  
Centers for Disease Control and Prevention

# Licensed vaccines to prevent pneumococcal disease

- Pneumococcal conjugate vaccine
  - PCV13 or Prevnar 13<sup>®</sup>
- Pneumococcal polysaccharide vaccine
  - PPSV23 or Pneumovax23<sup>®</sup>



# Current CDC pneumococcal vaccine recommendations

- **Routine immunization by age**
  - All infants, children: PCV13
  - All adults 65 years +: PCV13 and PPSV23
- **Certain indications**
  - Children 2 years +, adults: vaccine type and doses varies
    - Age
    - Vaccines previously received
    - Indication

Summarized in  
6 publications

## CURRENT Pneumococcal Vaccine Recommendations

- Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. [Recommendations of the Advisory Committee on Immunization Practices \(ACIP\). \*MMWR\*. 2014;63\(37\):822-5.](#)  
[Print version](#) [36 pages]
- Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. [Use of PCV-13 and PPSV-23 Vaccines Among Children Aged 6–18 Years with Immunocompromising Conditions. \*MMWR\*. 2014;63\(37\):822-5.](#)  
[Print version](#) [24 pages]
- *MMWR*, June 28, 2013, Vol 62, #25  
[Use of PCV-13 and PPSV-23 Vaccines Among Children Aged 6–18 Years with Immunocompromising Conditions. \*MMWR\*. 2013;62\(25\):507-11.](#)  
[Print version](#) [16 pages]
- *MMWR*, October 12, 2012, Vol 61, #40  
[Use of PCV13 and PPSV23 Vaccine for Adults with Immunocompromising Conditions. \*MMWR\*. 2012;61\(40\):847-51.](#)  
[Print version](#) [20 pages]
- *MMWR*, December 10, 2010, Vol 59, #RR-11  
[Prevention of Pneumococcal Disease Among Infants and Children—Use of PCV13 and PPSV23. \*MMWR\*. 2010;59\(11\):1-11.](#)  
[Print version](#) [24 pages]
- *MMWR*, September 3, 2010, Vol 59, #34  
[Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Aged 65 Years and Older—Use of PCV13 and PPSV23 Vaccine \(PPSV23\). \*MMWR\*. 2010;59\(34\):1103-11.](#)  
[Print version](#) [32 pages]

## Pneumococcal vaccine timing for adults with certain medical conditions

Indicated to receive 1 dose of PPSV23 at 19 through 64 years



### Includes adults with:

- chronic heart or lung disease
- diabetes mellitus
- alcoholism
- chronic liver disease

Also includes adults who smoke cigarettes

Indicated to receive 1 dose of PCV13 at ≥ 19 years



### Includes adults with:

- cerebrospinal fluid (CSF) leaks\*
- cochlear implants\*
- sickle cell disease or other hemoglobinopathies
- congenital or acquired asplenia
- congenital or acquired immunodeficiencies
- HIV infection
- chronic renal failure
- nephrotic syndrome
- leukemia
- lymphoma
- Hodgkin disease
- generalized malignancy
- iatrogenic immunosuppression
- solid organ transplant
- multiple myeloma

## Pneumococcal Vaccine Timing for Adults

Make sure your patients are up to date with pneumococcal vaccination.

Two pneumococcal vaccines are recommended for adults:

- 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13<sup>®</sup>)
- 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax<sup>®</sup>23)

PCV13 and PPSV23 should not be administered during the same office visit.

When both are indicated, PCV13 should be given before PPSV23 whenever possible.

If either vaccine is inadvertently given earlier than the recommended window, do not repeat the dose.

One dose of PCV13 is recommended for adults:


- 65 years or older who have not previously received PCV13.
- 19 years or older with certain medical conditions and who have not previously received PCV13. See Table 1 for specific guidance.

One dose of PPSV23 is recommended for adults:

- 65 years or older, regardless of previous history of vaccination with pneumococcal vaccines.
  - Once a dose of PPSV23 is given at age 65 years or older, no additional doses of PPSV23 should be administered.
- 19 through 64 years with certain medical conditions.
  - A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance.


## Pneumococcal vaccine timing for adults 65 years or older

For those who have not received any pneumococcal vaccines, or those with unknown vaccination history



- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 **at least 1 year** later for most immunocompetent adults or **at least 8 weeks** later for adults with immunocompromising conditions, cerebrospinal fluid leaks, or cochlear implants. See Table 1 for specific guidance.

For those who have previously received 1 dose of PPSV23 at ≥ 65 years and no doses of PCV13



- Administer 1 dose of PCV13 **at least 1 year** after the dose of PPSV23 for all adults, regardless of medical conditions.

NCIRDig410 | 11.30.2015

[www.cdc.gov/pneumococcal/vaccination.html](http://www.cdc.gov/pneumococcal/vaccination.html)




U.S. Department of Health and Human Services  
Centers for Disease Control and Prevention

<https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>


# New mobile app: Quick, easy to use



Enter patient's age  
(works for all ages)





Note any underlying  
medical conditions



Enter vaccination history

# Get customized recommendations for individual patients on which vaccines to give when



# **PneumoRecs** VaxAdvisor

---

Available for iOS and Android

[cdc.gov/vaccines/pneumoapp](https://cdc.gov/vaccines/pneumoapp)